7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
https://doi.org/10.1093/ofid/ofy210.1591
Copy DOIJournal: Open Forum Infectious Diseases | Publication Date: Nov 26, 2018 |
License type: CC BY-NC-ND 4.0 |
BackgroundAlthough OPAT is widely accepted practice for adults in the USA, the safety of OPAT in very old patients has not been examined before.MethodsThe Cleveland Clinic OPAT Registry was screened to identify patients aged 90 and above discharged from hospital on OPAT. Control subjects (those aged 89 years and younger) were selected from the OPAT registry, matched to study subjects on sex, year of admission, OPAT site, vascular access, infection category, and antibiotic group. ED visits, readmissions, and deaths, for nonagenarians and controls, were described as competing outcomes. Patients were only included once. Events up to 90 days following initiation of OPAT were considered. OPAT-related ED visits, and separately OPAT-related readmissions, were compared across the two groups in subdistribution proportional hazards competing risks regression models. Adverse drug events were compared using logistic regression.ResultsThirty nonagenarians and 87 control subjects were identified for patients discharged on OPAT between January 1, 2013 and May 21, 2014. Mean (SD) of age for nonagenarians and controls were 92 (3) and 61 (16), respectively, and 67 (57%) were males. Cardiovascular and osteoarticular infections accounted for more than 50% of infections treated in each group, and the majority of patients received their OPAT in skilled nursing facilities. The cumulative incidences of OPAT-related ED visits and readmissions for nonagenarians and control patients, with death and non-OPAT-related readmissions accounted for as competing events, are shown in the figure. Compared with matched patients below 90 years of age, nonagenarians were not at increased risk of OPAT-related ED visits (HR 1.32, 95% CI 0.55–3.18, P = 0.54), OPAT-related readmissions (HR 1.2, 95% CI 0.23–6.19, P = 0.83), or adverse drug events from OPAT medications (OR 1.22, 95% CI 0.28–8.55, P = 0.81).ConclusionOPAT can be accomplished in nonagenarians as safely as in younger patients. Disclosures All authors: No reported disclosures.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.